kth.sePublications
Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
Iterative nanoparticle bioengineering enabled by x-ray fluorescence imaging
KTH, School of Engineering Sciences (SCI), Applied Physics.ORCID iD: 0000-0002-6854-1423
KTH, School of Engineering Sciences (SCI), Applied Physics.ORCID iD: 0000-0003-0551-7976
KTH, School of Engineering Sciences (SCI), Applied Physics.ORCID iD: 0000-0002-9273-4823
KTH, School of Engineering Sciences (SCI), Applied Physics.ORCID iD: 0000-0001-5678-5298
Show others and affiliations
2024 (English)In: Science Advances, E-ISSN 2375-2548, Vol. 10, no 12, article id eadl2267Article in journal (Refereed) Published
Abstract [en]

Nanoparticles (NPs) are currently developed for drug delivery and molecular imaging. However, they often get intercepted before reaching their target, leading to low targeting efficacy and signal-to-noise ratio. They tend to accumulate in organs like lungs, liver, kidneys, and spleen. The remedy is to iteratively engineer NP surface properties and administration strategies, presently a time-consuming process that includes organ dissection at different time points. To improve this, we propose a rapid iterative approach using whole-animal x-ray fluorescence (XRF) imaging to systematically evaluate NP distribution in vivo. We applied this method to molybdenum-based NPs and clodronate liposomes for tumor targeting with transient macrophage depletion, leading to reduced accumulations in lungs and liver and eventual tumor detection. XRF computed tomography (XFCT) provided 3D insight into NP distribution within the tumor. We validated the results using a multiscale imaging approach with dye-doped NPs and gene expression analysis for nanotoxicological profiling. XRF imaging holds potential for advancing therapeutics and diagnostics in preclinical pharmacokinetic studies.

Place, publisher, year, edition, pages
American Association for the Advancement of Science (AAAS) , 2024. Vol. 10, no 12, article id eadl2267
National Category
Radiology, Nuclear Medicine and Medical Imaging
Identifiers
URN: urn:nbn:se:kth:diva-349610DOI: 10.1126/sciadv.adl2267ISI: 001250284900009PubMedID: 38517973Scopus ID: 2-s2.0-85188869462OAI: oai:DiVA.org:kth-349610DiVA, id: diva2:1881020
Note

QC 20240702

Available from: 2024-07-02 Created: 2024-07-02 Last updated: 2024-07-02Bibliographically approved

Open Access in DiVA

No full text in DiVA

Other links

Publisher's full textPubMedScopus

Authority records

Brodin, BerthaKakadiya, RonakHertz, Hans

Search in DiVA

By author/editor
Saladino, Giovanni MarcoBrodin, BerthaKakadiya, RonakToprak, Muhammet S.Hertz, Hans
By organisation
Applied Physics
In the same journal
Science Advances
Radiology, Nuclear Medicine and Medical Imaging

Search outside of DiVA

GoogleGoogle Scholar

doi
pubmed
urn-nbn

Altmetric score

doi
pubmed
urn-nbn
Total: 54 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf